David Dai

Stock Analyst at UBS

(0)
# 5000
Out of 5,346 analysts
25
Total ratings
15.79%
Success rate
-30.76%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
IOVA Iovance Biotherapeut...
Downgrades: Neutral
17 2
1.82 9.89% 2 May 16, 2025
CGEM Cullinan Therapeutic...
Maintains: Buy
30 24
8.69 176.18% 2 May 12, 2025
NUVL Nuvalent
Upgrades: Buy
100 100
74.79 33.71% 2 Mar 14, 2025
KURA Kura Oncology
Maintains: Buy
27 14
5.83 140.14% 2 Mar 6, 2025
IMCR Immunocore Hldgs
Initiates Coverage On: Sell
24
34.96 -31.35% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
88
103 -14.56% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
2.71 638.01% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
35
10.67 228.02% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
55.32 30.15% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
24.13 185.95% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
20.03 149.63% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
26.31 128.05% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
10.6 249.06% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.72 3788.89% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
13.68 192.4% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
1.41 2736.88% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
1.81 2662.43% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
32.95 57.81% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017